Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

New Alzheimer’s drug being partly developed in Aberdeen showing “promising results”

Prof Claude Wischik
Prof Claude Wischik

A new Alzheimer’s drug which is being developed partly in Aberdeen has shown “promising results” in recent studies – offering hope to millions of patients around the world.

Professor Claude Wischik first discovered that the building blocks of Alzheimer’s disease, named tau proteins – which can tangle within brain cells and spread like a virus – could be dissolved in the test tube with the right chemicals in the 1980s.

And for the last several years, he has been working on harnessing this reaction to provide an effective treatment for the deteriorative condition with teams at Aberdeen Royal Infirmary.

Recent clinical studies of his treatment, named LMTC, have shown positive signs of the drug’s effectiveness in slowing down and reducing the effects of the disease.

However, Prof Wischik’s team now need to carry out further tests before the drugs can be rolled out.

The results of the studies were presented at a recent Alzheimer’s Research UK conference, and last year in Canada and the US.

Prof Wischik said one of the key outcomes of the recent studies is the drug seems to be more effective when used as the

sole treatment.

He said: “Our first study was a comparison of two high doses of 150mg and 250mg a day of the drug, to a low dose of 8mg a day as control.

“That study showed there was no difference in the main outcomes at the different dosage levels across the study population as a whole, but it suggested that the drug might be effective as the sole therapy.

“In other words, it didn’t seem to work for patients who were taking the drug in combination with the standard treatments for Alzheimer’s disease.

“However, it looks as though the patients who were taking it as their only treatment did remarkably well – and the same was true even at the very low dose of only 8mg a day – which we assumed would not have been very effective – and that’s really good, because it’s a safer option, and is tolerated very well by patients.

“For these clinical outcomes, these patients had no decline, or only minimal decline, over the 15 months of the trial, whereas those who were taking the drug in combination with standard treatments declined as expected with Alzheimer’s disease.

“Those were promising results.”

Prof Wischik said it is hoped a new study can commence before the end of the year, and if the results are positive, it could be another significant step forward in the long-running battle against the devastating condition.